Enfortumab Vedotin — Drug Intelligence | 10 EU Trials

Filter these 10 trials by condition, phase, country and more.

Open in Search →

10 Registered trials

4 Recruiting

5 Completed trials

8 Sponsors

13 Countries

Phase III

Phase II

Phase I/II

Phase III: 3 Phase II: 6 Phase I/II: 1

Oversight events:

1 unexpected event across 1 trial

View oversight register →

Sponsors using this IMP

Astellas Pharma Global Development Inc. 2 Seagen Inc. 2 AstraZeneca AB 1 Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH 1 Gilead Sciences Inc. 1 Grupo Espanol De Tumores Neuroendocrinos 1 Grupo Espanol Multidisciplinar De Melanoma 1 Pfizer Inc. 1

All trials

10 total

A study to find out if enfortumab vedotin given with pembrolizumab helps people with muscle-invasive bladder cancer keep their bladder. Pending

2025-524488-18-00 Phase II 5 countries Astellas Pharma Global Development Inc.
Symbiotic-GU-06-A Study to Learn About the Study Medicine PF-08634404 Alone or In Combination With Enfortumab Vedotin in Adult Participants … Recruiting

2025-523523-21-00 Phase I/II 2 countries Pfizer Inc.
DEPECA-1 – DEfeating PEnile CAncer 1 – A Phase II study to evaluate a first-line systemic therapy with enfortumab vedotin plus avelumab for … Recruiting

2025-521644-37-00 Phase II 1 country Frankfurter Institut Fuer Klinische Krebsforschung IKF GmbH
Multicenter, open label, single arm, phase II study to assess the efficay and safety of enfortumab-vedotin (EV) as a single agent in patient… Recruiting

2024-515511-21-00 Phase II 1 country Grupo Espanol De Tumores Neuroendocrinos
A Phase II Open-Label Study of Sacituzumab Govitecan in Unresectable Locally Advanced/Metastatic Urothelial Cancer Recruiting

2023-508302-24-00 Phase II 5 countries Gilead Sciences Inc.
PLUG-IN. Phase 2 of pembrolizumab combined with enfortumab vedotin for advanced melanoma patients. Ended

2024-514163-26-00 Phase II 1 country Grupo Espanol Multidisciplinar De Melanoma
Treatment combination of Durvalumab, Tremelimumab, Enfortumab Vedotin in patients with muscle invasive bladder cancer ineligible to cisplati… Ended

2023-507342-84-00 Phase III 9 countries Astrazeneca AB
An open-label clinical trial evaluating enfortumab vedotin in combination with pembrolizumab versus chemotherapy alone in previously untreat… Ended

2023-503421-19-00 Phase III 10 countries Seagen Inc.
A study of enfortumab vedotin alone or in combination with other anticancer therapies for the treatment of urothelial cancer Ended

2023-503391-24-00 Phase II 1 country Seagen Inc.
A Study to Evaluate Enfortumab Vedotin Versus (vs) Chemotherapy in Subjects With Previously Treated Locally Advanced or Metastatic Urothelia… Ended

2024-517571-20-00 Phase III 2 countries Astellas Pharma Global Development Inc.

Showing 1–10 of 10 trials

← All drugs A–Z